文献速递肝病消化道肿瘤与早癌

二甲双胍降低台湾糖尿病合并慢性丙型肝炎患者抗病毒治疗成功后肝细胞癌发病率

Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
PubMed 文献 · J Hepatol · 2022-10-05

本研究基于台湾大规模多中心队列(T-COACH),纳入干扰素治疗后获得持续病毒学应答的慢性丙型肝炎患者,评估二甲双胍对肝细胞癌风险的影响。中位随访4.4年,二甲双胍使用者5年累积肝细胞癌发生率2.6%,非使用者10.9%,无糖尿病患者3.0%。结论认为二甲双胍大幅降低糖尿病合并慢性丙型肝炎患者抗病毒治疗成功后的肝细胞癌风险。

要点

  • 糖尿病合并慢性丙型肝炎患者抗病毒治疗成功后,使用二甲双胍者5年累积肝细胞癌发生率2.6%,未使用者10.9%。
  • 以肝硬化和糖尿病未使用二甲双胍两个因素构建的简易风险模型可预测持续病毒学应答后肝细胞癌风险。
  • 作者强烈推荐糖尿病合并慢性丙型肝炎患者在病毒清除后使用二甲双胍以降低肝细胞癌风险。

核心结论

  • 二甲双胍大幅降低糖尿病合并慢性丙型肝炎患者抗病毒治疗成功后的肝细胞癌风险。
  • 由肝硬化和糖尿病未使用二甲双胍构成的简易风险分层模型可预测持续病毒学应答后的长期结局。
  • 作者强烈推荐糖尿病合并慢性丙型肝炎患者在病毒清除后使用二甲双胍以降低肝细胞癌风险。

研究设计与样本

  • 研究为台湾大规模多中心队列(T-COACH),纳入干扰素为基础治疗后获得持续病毒学应答的慢性丙型肝炎患者。
  • 通过链接重大伤病与癌症登记数据库识别持续病毒学应答至少1年后发生的肝细胞癌病例。
  • 共纳入7249例慢性丙型肝炎患者,其中781例(10.8%)合并糖尿病,647例(82.8%)为二甲双胍使用者。

主要发现

  • 中位随访4.4年期间,227例患者发生新发肝细胞癌。
  • 5年累积肝细胞癌发生率:二甲双胍使用者2.6%,非使用者10.9%,无糖尿病患者3.0%。
  • 与非糖尿病患者相比,糖尿病未使用二甲双胍者调整风险比2.83(95%CI 1.57-5.08),糖尿病使用二甲双胍者调整风险比1.46(95%CI 0.98-2.19)。
  • Cox回归分析中,肝硬化是与较高肝细胞癌风险显著相关的最重要因素,其次为糖尿病未使用二甲双胍、高龄、男性与肥胖;合并高脂血症使用他汀与较低肝细胞癌风险相关。
  • 二甲双胍使用降低所有肝脏相关并发症的风险。

关键数值与推荐

  • 由肝硬化和糖尿病未使用二甲双胍两个最关键风险因素构建的简易风险模型可预测持续病毒学应答后肝细胞癌风险。

临床怎么用

  • 作者强烈推荐糖尿病合并慢性丙型肝炎患者在病毒清除后使用二甲双胍以降低肝细胞癌风险。
  • 作者认为,尽管抗病毒治疗成功大幅降低肝细胞癌风险,合并肝硬化、糖尿病、肥胖及高龄者仍属肝细胞癌高危人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Diabetes mellitus (DM) is known to increase the risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate whether metformin reduces HCC risk among individuals with DM and CHC after successful antiviral therapy. METHODS: Individuals with CHC who achieved a sustained virological response (SVR) after interferon-based therapy were enrolled in a large-scale, multicenter cohort in Taiwan (T-COACH). Cases of HCC at least 1 year after SVR were identified through linkage to the catastrophic illness and cancer registry databases. RESULTS: Of 7,249 individuals with CHC enrolled in the study, 781 (10.8%) had diabetes and 647 (82.8%) were metformin users. During a median follow-up of 4.4 years, 227 patients developed new-onset HCC. The 5-year cumulative HCC incidence was 10.9% in non-metformin users and 2.6% in metformin users, compared to 3.0% in individuals without DM (adjusted hazard ratio [aHR] 2.83; 95% CI 1.57-5.08 and aHR 1.46; 95% CI 0.98-2.19, respectively). Cirrhosis was the most important factor significantly associated with higher HCC risk in Cox regression analysis, followed by DM non-metformin use, older age, male sex, and obesity; whereas hyperlipidemia with statin use was associated with a lower HCC risk. Using the two most crucial risk factors, cirrhosis and DM non-metformin use, we constructed a simple risk model that could predict HCC risk among individuals with CHC after SVR. Metformin use was shown to reduce the risk of all liver-related complications. CONCLUSIONS: Metformin use greatly reduced HCC risk after successful antiviral therapy in individuals with diabetes and CHC. A simple risk stratification model comprising cirrhosis and DM non-metformin use could predict long-term outcomes in individuals with CHC after SVR. IMPACT AND IMPLICATIONS: The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study. Although successful antiviral therapy greatly reduces HCC risk in individuals with chronic hepatitis C, those with cirrhosis, diabetes, obesity, and the elderly remain at high risk of HCC development. We demonstrated that a simple risk model composed of two crucial unfavorable factors, cirrhosis and diabetes without metformin use, predicts the risk of HCC and major liver-related complications after successful antiviral therapy in individuals with chronic hepatitis C. Metformin use is highly recommended for individuals with diabetes and chronic hepatitis C after viral eradication to reduce the risk of HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Tsai PC, Kuo HT, Hung CH, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2022. PMID: 36208843. doi:10.1016/j.jhep.2022.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。